SI2215072T1 - Polimorfna oblika rotigotina - Google Patents
Polimorfna oblika rotigotinaInfo
- Publication number
- SI2215072T1 SI2215072T1 SI200831499T SI200831499T SI2215072T1 SI 2215072 T1 SI2215072 T1 SI 2215072T1 SI 200831499 T SI200831499 T SI 200831499T SI 200831499 T SI200831499 T SI 200831499T SI 2215072 T1 SI2215072 T1 SI 2215072T1
- Authority
- SI
- Slovenia
- Prior art keywords
- rotigotine
- polymorphic form
- polymorphic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99072107P | 2007-11-28 | 2007-11-28 | |
EP07121795 | 2007-11-28 | ||
EP08166576 | 2008-10-14 | ||
PCT/EP2008/066137 WO2009068520A2 (en) | 2007-11-28 | 2008-11-25 | Polymorphic form of rotigotine |
EP08853236.1A EP2215072B1 (en) | 2007-11-28 | 2008-11-25 | Polymorphic form of rotigotine |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2215072T1 true SI2215072T1 (sl) | 2015-10-30 |
Family
ID=40676399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200831499T SI2215072T1 (sl) | 2007-11-28 | 2008-11-25 | Polimorfna oblika rotigotina |
Country Status (28)
Country | Link |
---|---|
US (2) | US8592477B2 (sl) |
EP (1) | EP2215072B1 (sl) |
JP (1) | JP5391204B2 (sl) |
KR (1) | KR101694551B1 (sl) |
CN (1) | CN101970422B (sl) |
AR (1) | AR070036A1 (sl) |
AU (1) | AU2008328920B2 (sl) |
CA (1) | CA2703561C (sl) |
DK (1) | DK2215072T3 (sl) |
EA (1) | EA017836B1 (sl) |
ES (1) | ES2547231T3 (sl) |
HK (1) | HK1143162A1 (sl) |
HR (1) | HRP20150956T1 (sl) |
HU (1) | HUE027647T2 (sl) |
IL (1) | IL204991A (sl) |
ME (1) | ME02275B (sl) |
MX (1) | MX2010005925A (sl) |
MY (1) | MY165575A (sl) |
NZ (1) | NZ584363A (sl) |
PH (1) | PH12013501503A1 (sl) |
PL (1) | PL2215072T3 (sl) |
PT (1) | PT2215072E (sl) |
RS (1) | RS54235B1 (sl) |
SG (1) | SG10201610626PA (sl) |
SI (1) | SI2215072T1 (sl) |
TW (1) | TWI418349B (sl) |
WO (1) | WO2009068520A2 (sl) |
ZA (1) | ZA201002192B (sl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
SI1750766T1 (sl) | 2004-05-11 | 2013-11-29 | Emotional Brain B.V. | Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
KR20100022081A (ko) | 2007-05-30 | 2010-02-26 | 케마지스 리미티드 | 결정성 로티고틴 염기 및 이의 제조 방법 |
ME02275B (me) * | 2007-11-28 | 2016-02-20 | Ucb Pharma Gmbh | Polimorfni oblik rotigotina |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
AU2010334805B2 (en) | 2009-12-22 | 2015-01-22 | Lts Lohmann Therapie-Systeme Ag | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
WO2013075822A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system (tts) with rotigotine |
DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
TW201431570A (zh) * | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
WO2014136122A1 (en) * | 2013-03-04 | 2014-09-12 | Mylan Laboratories Limited | Process for the preparation of rotigotine polymorphic form-i |
US10046151B2 (en) | 2013-07-03 | 2018-08-14 | Lts Lohmann Therapie-Systeme, Ag | Transdermal therapeutic system with electronic component |
ES2954087T3 (es) | 2014-05-20 | 2023-11-20 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que incluye un mediador de interfase |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
US11633367B2 (en) | 2014-05-20 | 2023-04-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
WO2015186138A1 (en) * | 2014-06-03 | 2015-12-10 | Davaluri Ramamohan Rao | Improved process for the preparation of crystalline form ii of rotigotine |
WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
EP3730129B1 (en) | 2017-12-19 | 2024-08-07 | Hisamitsu Pharmaceutical Co., Inc. | Rotigotine-containing patch |
KR20210104101A (ko) | 2019-02-15 | 2021-08-24 | 히사미쓰 세이야꾸 가부시키가이샤 | 로티고틴 안정화 방법 |
PL3854388T3 (pl) | 2020-01-24 | 2024-02-26 | Luye Pharma Switzerland Ag | Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4320148A (en) | 1980-11-24 | 1982-03-16 | Smithkline Corporation | 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity |
US5177112A (en) | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US4540691A (en) | 1984-04-13 | 1985-09-10 | Nelson Research & Development Co. | Dopamine agonists and use thereof |
US4885308A (en) | 1984-08-13 | 1989-12-05 | Nelson Research & Development Co. | Method and compositions for treatment of parkinsonism syndrome in mammals |
US5214156A (en) | 1988-03-25 | 1993-05-25 | The Upjohn Company | Therapeutically useful tetralin derivatives |
HUT61719A (en) | 1989-05-31 | 1993-03-01 | Upjohn Co | Process for producing 2-aminotetraline derivatives and pharmaceutical compositions comprising such compounds |
US5545755A (en) | 1989-05-31 | 1996-08-13 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
US5486611A (en) | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
US5071875A (en) | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
US5151446A (en) | 1989-09-25 | 1992-09-29 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
SE9301732D0 (sv) | 1993-05-18 | 1993-05-18 | Haakan Wilhelm Wikstroem | New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins |
US5382596A (en) | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19814083C2 (de) | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
DK1232152T3 (da) * | 1999-11-23 | 2004-04-05 | Aderis Pharmaceuticals Inc | Forbedret fremgangsmåde til fremstilling af nitrogensubstituerede aminotetraliner |
DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20030027793A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
ES2203563T3 (es) | 2001-05-08 | 2004-04-16 | Schwarz Pharma Ag | Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson. |
FR2828212B1 (fr) | 2001-08-03 | 2003-10-31 | Aventis Pharma Sa | Methodes de diagnostic et de pronostic de la maladie de parkinson |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
EP1494664A2 (en) | 2002-04-18 | 2005-01-12 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
US8211462B2 (en) | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US7038085B2 (en) | 2002-10-25 | 2006-05-02 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
ES2239196T3 (es) | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US7348762B2 (en) | 2003-05-01 | 2008-03-25 | Sony Corporation | Battery pack and method for producing battery pack |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
AU2005319367B2 (en) | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1987815A1 (en) | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
KR20100022081A (ko) * | 2007-05-30 | 2010-02-26 | 케마지스 리미티드 | 결정성 로티고틴 염기 및 이의 제조 방법 |
WO2009063170A1 (en) | 2007-11-16 | 2009-05-22 | Pliva Hrvatska D.O.O. | Preparation of crystalline rotigotine base |
ME02275B (me) | 2007-11-28 | 2016-02-20 | Ucb Pharma Gmbh | Polimorfni oblik rotigotina |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
AU2010334805B2 (en) | 2009-12-22 | 2015-01-22 | Lts Lohmann Therapie-Systeme Ag | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
WO2015186138A1 (en) | 2014-06-03 | 2015-12-10 | Davaluri Ramamohan Rao | Improved process for the preparation of crystalline form ii of rotigotine |
-
2008
- 2008-11-25 ME MEP-2015-136A patent/ME02275B/me unknown
- 2008-11-25 AU AU2008328920A patent/AU2008328920B2/en active Active
- 2008-11-25 PT PT88532361T patent/PT2215072E/pt unknown
- 2008-11-25 PL PL08853236T patent/PL2215072T3/pl unknown
- 2008-11-25 HU HUE08853236A patent/HUE027647T2/en unknown
- 2008-11-25 RS RS20150578A patent/RS54235B1/en unknown
- 2008-11-25 US US12/744,989 patent/US8592477B2/en active Active
- 2008-11-25 SI SI200831499T patent/SI2215072T1/sl unknown
- 2008-11-25 WO PCT/EP2008/066137 patent/WO2009068520A2/en active Application Filing
- 2008-11-25 NZ NZ584363A patent/NZ584363A/xx unknown
- 2008-11-25 CN CN200880110877.9A patent/CN101970422B/zh not_active Ceased
- 2008-11-25 ES ES08853236.1T patent/ES2547231T3/es active Active
- 2008-11-25 EA EA201000384A patent/EA017836B1/ru not_active IP Right Cessation
- 2008-11-25 MX MX2010005925A patent/MX2010005925A/es active IP Right Grant
- 2008-11-25 DK DK08853236.1T patent/DK2215072T3/en active
- 2008-11-25 KR KR1020107010562A patent/KR101694551B1/ko active IP Right Review Request
- 2008-11-25 JP JP2010535352A patent/JP5391204B2/ja active Active
- 2008-11-25 SG SG10201610626PA patent/SG10201610626PA/en unknown
- 2008-11-25 MY MYPI2010001680A patent/MY165575A/en unknown
- 2008-11-25 EP EP08853236.1A patent/EP2215072B1/en not_active Revoked
- 2008-11-25 CA CA2703561A patent/CA2703561C/en active Active
- 2008-11-26 TW TW097145595A patent/TWI418349B/zh active
- 2008-11-26 US US12/324,166 patent/US8232414B2/en active Active
- 2008-11-28 AR ARP080105189A patent/AR070036A1/es unknown
-
2010
- 2010-03-29 ZA ZA2010/02192A patent/ZA201002192B/en unknown
- 2010-04-11 IL IL204991A patent/IL204991A/en active IP Right Grant
- 2010-10-14 HK HK10109729.7A patent/HK1143162A1/xx unknown
-
2013
- 2013-07-15 PH PH12013501503A patent/PH12013501503A1/en unknown
-
2015
- 2015-09-10 HR HRP20150956TT patent/HRP20150956T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL204991A0 (en) | Polymorphic form of rotigotine | |
GB2446847B (en) | Location of Basestation | |
EP2361340A4 (en) | SEAL TRIM | |
EP2275418A4 (en) | CHROME COMPOUND | |
GB0711697D0 (en) | Method of manufacture | |
ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
EP2242493A4 (en) | Gefitinib DERIVATIVES | |
IL211290A0 (en) | New 2-amidothiadiazole derivatives | |
IL210613A0 (en) | Novel acylaminobenzamide derivatives | |
PL2133419T3 (pl) | Zastosowania beta-dipeptydów cyjanoficyny | |
EP2212251A4 (en) | PROCESS FOR THE PRODUCTION OF CLUSTERBOR | |
HK1147481A1 (en) | Polymorphic form | |
IL200930A0 (en) | Handoff of data attachment point | |
HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
EP2205525A4 (en) | PROCESS FOR THE PREPARATION OF CLUSTERBORON | |
EP2211616A4 (en) | PROCESS FOR PREPARING IMIDAZOAZEPINONE COMPOUNDS | |
EP2205524A4 (en) | METHODS OF MANUFACTURING CLUSTER BORON | |
EP2331490A4 (en) | PREPARATION OF DIBUTOXYMETHANE | |
GB0821185D0 (en) | Walking aid | |
GB201114396D0 (en) | Location of basesation | |
PL383760A1 (pl) | Nowe zastosowanie undekan-2-olu | |
PL383758A1 (pl) | Nowe zastosowanie undekan-2-onu | |
PL383759A1 (pl) | Nowe zastosowanie undekan-2-olu | |
GB0821710D0 (en) | Derivatives of dihydroindolone | |
PL386302A1 (pl) | Nowa pochodna izotiazolopirydyny |